A phase II study of pacritinib in patients with myelofibrosis demonstrated that pacritinib is active in patients with myelofibrosis, resulting in spleen volume reduction, while producing substantial and prolonged improvement in disease-related symptoms without causing clinically significant myelosuppression.
Readers of The Cancer Letter and listeners of The Cancer Letter Podcast are familiar with the impact of President Donald Trump’s first nine months in office on the field of oncology. Now, the threats posed to oncology are being brought to the attention of a general audience—Jonathan Mahler, staff writer for The New York Times Magazine, wrote an in-depth article about how the Trump administration’s actions have brought chaos, uncertainty, and damage to the oncology research community.
